Allergy Asthma Respir Dis.  2017 Jul;5(4):232-236. 10.4168/aard.2017.5.4.232.

Myeloid and lymphoid neoplasm with eosinophilia and abnormalities of PDGFRB presenting as congestive heart failure and hypereosinophilia

  • 1Department of Allergy and Clinical Immunology, Kangwon National University School of Medicine, Chuncheon, Korea.
  • 2Department of Internal Medicine, Chungbuk National College of Medicine, Cheongju, Korea.
  • 3ivision of Cardiology, Department of Internal Medicine, Kangwon National University School of Medicine, Chuncheon, Korea.


Hypereosinophilic syndrome (HES) is a heterogeneous disorder characterized by persistent hypereosinophilia with the evidence of organ dysfunction caused by eosinophilic involvement. HES can be induced by various secondary causes, including helminthic infections, adverse drug reactions, and allergic diseases. Primary/clonal bone marrow disease, including genetic mutations in platelet driven growth factor receptor alpha (PDGFRA), platelet driven growth factor receptor beta (PDGFRB), and fibroblast growth factor receptor 1 (FGFR1) could be its causes. Although corticosteroids are the mainstay of therapy in confirmed HES, imatinib is considered a definitive treatment for HES with these mutations. However, there have been few reports about HES with these genetic mutations in Korea. Here, we report a patient who presented with sudden onset of congestive heart failure and hypereosinophilia, proved to have PDGFRB rearrangement, and was controlled successfully with imatinib after left ventricle thrombectomy.


Hypereosinophilic syndrome; PDGFRB; Imatinib; Eosinophilia
Full Text Links
  • AARD
  • Twitter
  • Facebook
Copyright © 2020 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: